These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33168323)

  • 1. Combination therapy in metastatic renal cell carcinoma: Back to the future?
    Cerbone L; Cattrini C; Vallome G; Latocca MM; Boccardo F; Zanardi E
    Semin Oncol; 2020 Dec; 47(6):361-366. PubMed ID: 33168323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.
    de Velasco G; Bex A; Albiges L; Powles T; Rini BI; Motzer RJ; Heng DYC; Escudier B
    Eur Urol Oncol; 2019 Sep; 2(5):505-514. PubMed ID: 31377308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
    Soleimani M; Nappi L; Kollmannsberger C
    Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of selected gastrointestinal toxicities in metastatic renal cell carcinoma patients treated with immuno-TKI combinations: a meta-analysis.
    Rizzo A; Mollica V; Santoni M; Massari F
    Expert Rev Gastroenterol Hepatol; 2021 Oct; 15(10):1225-1232. PubMed ID: 34167420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibition for the treatment of renal cell carcinoma.
    Stühler V; Maas JM; Rausch S; Stenzl A; Bedke J
    Expert Opin Biol Ther; 2020 Jan; 20(1):83-94. PubMed ID: 31587590
    [No Abstract]   [Full Text] [Related]  

  • 10. Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma.
    Spisarová M; Melichar B; Vitásková D; Študentová H
    Expert Rev Anticancer Ther; 2021 Jul; 21(7):693-703. PubMed ID: 33794744
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunotherapy for kidney cancer: status quo and the future.
    Bedke J; Stühler V; Stenzl A; Brehmer B
    Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances and future directions in the management of metastatic renal cell carcinoma.
    Ansari J; Glaholm J; McMenemin R; James ND; Hussain SA
    Anticancer Agents Med Chem; 2010 Mar; 10(3):225-35. PubMed ID: 20184547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options.
    Loo V; Salgia M; Bergerot P; Philip EJ; Pal SK
    Target Oncol; 2019 Dec; 14(6):639-645. PubMed ID: 31595385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
    Gill DM; Hahn AW; Hale P; Maughan BL
    Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell checkpoint inhibitors in metastatic renal cell carcinoma.
    Grünwald V
    Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence.
    Rizzo A; Rosellini M; Marchetti A; Mollica V; Massari F
    Immunotherapy; 2021 Jun; 13(8):685-692. PubMed ID: 33823678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
    Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
    Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy for renal cell carcinoma - current status].
    Grimm MO; Foller S
    Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.